US 11,873,287 B2
Piperidine-2,6-dione derivatives and ulcerative colitis treating
Hesheng Zhang, Tianjin (CN); and Guanghuai Zeng, Tianjin (CN)
Assigned to Tianjin Hemay Pharmaceutical Sci-Tech Co., Ltd, Tianjin (CN); and Ganzhou Hemay Pharmaceutical, Co., Ltd, Ganzhou (CN)
Filed by TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD, Tianjin (CN); and GANZHOU HEMAY PHARMACEUTICAL, CO., LTD, Ganzhou (CN)
Filed on Jun. 3, 2022, as Appl. No. 17/832,518.
Application 17/832,518 is a division of application No. 16/464,224, granted, now 11,485,724, previously published as PCT/CN2017/112668, filed on Nov. 23, 2017.
Claims priority of application No. 201611041317.5 (CN), filed on Nov. 24, 2016.
Prior Publication US 2022/0306600 A1, Sep. 29, 2022
Int. Cl. C07D 401/04 (2006.01); A61P 1/00 (2006.01); A61P 1/04 (2006.01); A61P 9/08 (2006.01); A61K 9/08 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01)
CPC C07D 401/04 (2013.01) [A61P 1/00 (2018.01); A61P 1/04 (2018.01); A61K 9/08 (2013.01); A61K 9/2018 (2013.01); A61K 9/4891 (2013.01)] 14 Claims
 
1. A piperidine-2,6-dione derivative being selected from the group consisting of:
4-amino-2-(1-(2-hydroxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
4-amino-5-hydroxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
4-amino-5-fluoro-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
4-amino-7-hydroxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
4-acetylamino-2-(1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
4-fluoro-2-(1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
5-amino-2-(1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
4-fluoro-2-(1-(2-ethoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
5-fluoro-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
4-amino-2-(1-(2-methoxybutyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
4-hydroxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
4-methyl-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
4-amino-5-methoxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione and pharmaceutically acceptable salts thereof; and
4-amino-2-(1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof.